Alanazi, W.A.; Alharbi, T.; El-Nagar, D.M.; Albogami, A.M.; Alswayyed, M.
Dapagliflozin Mitigates Hypotension in Lipopolysaccharide-Induced Acute Inflammation Independent of Glycemia Level. Pharmaceutics 2023, 15, 1683.
https://doi.org/10.3390/pharmaceutics15061683
AMA Style
Alanazi WA, Alharbi T, El-Nagar DM, Albogami AM, Alswayyed M.
Dapagliflozin Mitigates Hypotension in Lipopolysaccharide-Induced Acute Inflammation Independent of Glycemia Level. Pharmaceutics. 2023; 15(6):1683.
https://doi.org/10.3390/pharmaceutics15061683
Chicago/Turabian Style
Alanazi, Wael A., Turki Alharbi, Doaa M. El-Nagar, Abdullah M. Albogami, and Mohammed Alswayyed.
2023. "Dapagliflozin Mitigates Hypotension in Lipopolysaccharide-Induced Acute Inflammation Independent of Glycemia Level" Pharmaceutics 15, no. 6: 1683.
https://doi.org/10.3390/pharmaceutics15061683
APA Style
Alanazi, W. A., Alharbi, T., El-Nagar, D. M., Albogami, A. M., & Alswayyed, M.
(2023). Dapagliflozin Mitigates Hypotension in Lipopolysaccharide-Induced Acute Inflammation Independent of Glycemia Level. Pharmaceutics, 15(6), 1683.
https://doi.org/10.3390/pharmaceutics15061683